News

Minerva Announces Amended Agreement for MIN-202 in Insomnia

WALTHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has entered into a binding term sheet to amend its co-development and license agreement with Janssen Pharmaceutica NV (Janssen) related to MIN-202 (JNJ 42827922), a selective orexin-2 receptor antagonist, and to repurchase all Minerva shares owned by Johnson & Johnson Innovation – JJDC, Inc. (an affiliate of Janssen). ┬áThis amendment and the stock repurchase are conditional upon the closing of the pending acquisition of Actelion Ltd. by affiliates of Janssen and approval by the European Commission.

2017-06-20T16:39:20+00:00